Cell and Gene Therapy Manufacturing Market Research and Forecast 2023 to 2033
The global Cell and Gene Therapy Manufacturing Market is worth US$ 19.3 Billion as of now and expected to reach US$ 240 Billion by the year 2033 at a staggering CAGR of 29% between 2023 and 2033. The changing landscape of treating chronic ailments through advanced therapies is the key factor driving the cell and gene therapy manufacturing market. The key players have expanded their manufacturing capabilities regarding vector production and have also undertaken several strategic initiatives for producing investigational therapies. Along these lines, BioCardia Inc., in April 2022, did declare that the US FDA approved its IND applications for Covid-19 stem cell therapy to treat patients recovering from Acute Respiratory Distress owing to SARS-CoV-2. As of May 2022, ~300 cell and gene therapies are under clinical trial and expected to grow on a significant count in the years to come. Research states that nearly 35% of process gets outsourced with conventional biologics and over 65% ...